NasdaqGM:NTLABiotechs
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial
Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety monitoring protocols.
See our latest analysis for Intellia Therapeutics.
The FDA decision arrives after a sharp run, with a 30 day share price return of 42.78% and a year to date share price return of 42.78%, yet the 3 year total shareholder return of 69.58% and 5 year total shareholder return...